10x Genomics (TXG) to Release Earnings on Thursday

10x Genomics (NASDAQ:TXG) is projected to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect 10x Genomics to announce earnings of ($0.2431) per share and revenue of $146.6740 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.19. The firm had revenue of $150.84 million for the quarter, compared to the consensus estimate of $146.41 million. 10x Genomics had a negative net margin of 3.55% and a negative return on equity of 2.86%. The business’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.28) earnings per share. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Price Performance

Shares of 10x Genomics stock opened at $47.86 on Wednesday. 10x Genomics has a 52-week low of $11.16 and a 52-week high of $50.34. The firm has a market capitalization of $6.08 billion, a PE ratio of -281.53 and a beta of 2.03. The company’s fifty day moving average price is $38.02 and its two-hundred day moving average price is $27.09.

Insiders Place Their Bets

In other news, CFO Adam Taich sold 15,098 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $24.44, for a total value of $368,995.12. Following the transaction, the chief financial officer directly owned 379,898 shares of the company’s stock, valued at $9,284,707.12. The trade was a 3.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Serge Saxonov sold 30,000 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $34.44, for a total value of $1,033,200.00. Following the sale, the chief executive officer owned 1,108,380 shares in the company, valued at approximately $38,172,607.20. This trade represents a 2.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 91,309 shares of company stock valued at $2,581,357 over the last quarter. 8.84% of the stock is owned by insiders.

Institutional Trading of 10x Genomics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Van ECK Associates Corp lifted its position in 10x Genomics by 85.9% during the 4th quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock worth $60,000 after buying an additional 1,695 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in 10x Genomics by 203.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock valued at $87,000 after acquiring an additional 5,025 shares in the last quarter. Focus Partners Wealth acquired a new stake in 10x Genomics in the 1st quarter valued at about $92,000. CIBC Bancorp USA Inc. bought a new position in shares of 10x Genomics in the third quarter worth about $134,000. Finally, EP Wealth Advisors LLC bought a new position in shares of 10x Genomics in the fourth quarter worth about $188,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TXG. TD Cowen reissued a “hold” rating on shares of 10x Genomics in a research report on Wednesday, July 15th. Canaccord Genuity Group raised their target price on 10x Genomics from $32.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Piper Sandler boosted their price target on 10x Genomics from $20.00 to $42.00 and gave the company a “neutral” rating in a research note on Wednesday, July 1st. Leerink Partners increased their price objective on 10x Genomics from $23.00 to $40.00 and gave the stock a “market perform” rating in a research note on Friday, July 17th. Finally, JPMorgan Chase & Co. boosted their target price on shares of 10x Genomics from $17.00 to $20.00 and gave the company a “neutral” rating in a research note on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, 10x Genomics presently has an average rating of “Hold” and a consensus target price of $32.08.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.